VANCOUVER, BC / ACCESSWIRE / October 30, 2017 / LED Medical Diagnostics Inc. (''LED'' or the ''Company'') (OTCQB: LEDIF, TSX-V: LMD; FRA: LME) is pleased to announce the closing of a CDN$2,500,000 financing through the issuance of 12% second secured debentures of the Company (the ''Debentures'') maturing 24 months from the closing date (the ''Closing Date''). The Debentures were issued as part of a brokered private placement of 250 units (each, a ''Unit''), with each Unit consisting of: (i) a Debenture in the principal amount of CDN$10,000; and (ii) 21,250 common shares of the Company. The subscription price for the units was CDN$10,000 per unit. The rights of the subscribers of the Debentures and the related security are subordinated to the rights of the holders of debentures previously issued by the Company.
Certain insiders of LED, including a director and officer, acquired 10 units in the offering.
The Company granted the common shares as a loan bonus in accordance with Policy 5.1 of the TSX Venture Exchange (the ''TSX-V'').
Bloom Burton Securities Inc. acted as sole agent (the ''Agent'') to LED for the financing. In connection with the offering, the Agent received a cash commission of CDN$88,800 and 888,000 non-transferable warrants (the ''Warrants''). Each Warrant entitles the holder to acquire one common share in the capital of LED for a period of 24 months from the closing date at an exercise price of CDN$0.10 per share.
The proceeds will be used by LED to fund inventory purchases, working capital, and for general corporate purposes.
All securities issued in connection with the transaction will be subject to a hold period expiring four months and one day after the Closing Date.
LED also announces that it intends to effect a consolidation of its common shares on a 10 for 1 basis. The consolidation is expected to take effect around the end of November 2017, subject to obtaining all required approvals, including the approval of the TSX Venture Exchange. Assuming no other change in the issued capital of the Company, it is expected that upon completion of the consolidation LED will have approximately 37,914,637 common shares issued and outstanding, reduced from 379,146,372 common shares that are currently issued and outstanding. LED will announce further details of the consolidation upon obtaining all necessary approvals.
Dr. David Gane, CEO of LED, stated, ''The increased share price post consolidation is expected to make LED more attractive to institutional investors and easier to do business with Dental Support Organizations clients and other corporate customers for our unique offering of imaging products and services. It will also more accurately reflect the size and potential of our business.''
About LED Medical Diagnostics, Inc.
LED Medical Diagnostics Inc. is a dental imaging technology provider focused on delivering state-of-the-art imaging software and systems. Through its wholly-owned subsidiaries LED Dental Inc., LED Dental Ltd., and Apteryx, Inc., LED Medical has provided dentists and oral health specialists with advanced diagnostic imaging products and software for over 20 years. LED's proprietary technologies include the VELscope Vx Enhanced Oral Assessment and TUXEDO Intraoral Sensors, in addition to Apteryx's XrayVision, XVWeb and XrayVision DCV imaging software solutions.
Backed by an experienced leadership team and dedicated to a higher level of service and support, LED is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio. The Company is currently listed on the TSX-V under the symbol LMD, the OTCQB under the symbol LEDIF, as well as the Frankfurt Stock Exchange under the symbol LME.
Investor Relations:
Bristol Capital
Glen Akselrod
Phone: 905.326.1888 ext 10
Email: glen@bristolir.com
Media Contact:
LED Dental
Chris Koch
Phone: 678.293.9413
Email: chris.koch@leddental.com
Corporate Contact:
LED Medical
David Gane, CEO
Phone: 604.434.4614 ext 227
Email: david.gane@leddental.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involves risks and uncertainties. Such forward-looking statements or information include statements regarding, but not limited to, the expected use of proceeds of the financing and the expectation to affect the share consolidation including the expectation that LED will be more attractive to institutional investors and easier to do business with Dental Support Organizations clients and other corporate customers. Persons reading this press release are cautioned that such statements or information are only predictions and that the Company's actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to: failure to obtain regulatory approval for the consolidation; economic conditions; dilution; limited history of profits and operations; operational risk; distributor risks; working capital; potential conflicts of interest; speculative investment; intellectual property risks; disruptions in production; reliance on key personnel; seasonality; management's estimates; development of new customers and products risks; stock price volatility risk; sales and marketing risk; competitors and competition risk; regulatory requirements; reliance on few suppliers; reliance on subcontractors; operating cost and quarterly results fluctuations; fluctuations in exchange rates; product liability and medical malpractice claims; access to credit and additional financing; taxation; market acceptance of the Company's products and services; customer and industry analyst perception of the Company and its technology vision and future prospects; technological change, new products and standards; risks related to acquisitions and international expansion; reliance on large customers; concentration of sales; international operations and sales; management of growth and expansion; dependence upon key personnel and hiring; the Company not adequately protecting its intellectual property; risks related to product defects and product liability; reliance on third party suppliers; future working capital investments in accounts receivable and inventory; credit terms from suppliers; and including, but not limited to, other factors described in the Company's reports filed on SEDAR, including its financial statements and management's discussion and analysis for the three and six months ended June 30, 2017 and its Annual Information Form and financial report for the year ended December 31, 2016. This list is not exhaustive of the factors that may affect the Company's forward-looking information. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE: LED Medical Diagnostics Inc.
ReleaseID: 479636
